Active	Status	Sponsor type	Region	Phase	Filter
1 Active 2 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
agerafenib (RXDX-105) / Roche, Daiichi Sankyo
NCT03052569: Expanded Access to RXDX-105 for Cancers With RET Alterations	No Longer Available	N/A		US	RXDX-105	Hoffmann-La Roche	Cancers With RET Alterations